HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

Published:2013-10 Issue:6 Volume:39 Page:622-631
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Dent Susan,Oyan Basak,Honig Arnd,Mano Max,Howell Sacha

Funder

F. Hoffmann-La Roche Ltd., Basel, Switzerland

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference88 articles.

1. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;Mauri;J Natl Cancer Inst,2005

2. Preoperative chemotherapy for women with operable breast cancer;van der Hage;Cochrane Database Syst Rev,2007

3. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate;Chevallier;Am J Clin Oncol,1993

4. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy;Sinn;Geburtshilfe Frauenheilkd,1994

5. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome;Sataloff;J Am Coll Surg,1995

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator;Cancer Research Communications;2024-08-01

2. Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine;Journal of Personalized Medicine;2024-07-03

3. Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells;Turkish Journal of Biology;2024-02-27

4. Preoperative considerations and benefits of neoadjuvant chemotherapy: insights from a 12-year review of the Hong Kong Breast Cancer Registry;Hong Kong Medical Journal;2023-04-06

5. Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences;Biomedicine & Pharmacotherapy;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3